Vergelijking
DSIP vs. Icatibant
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
62568-57-4
138614-30-9
Molecuulmassa
848.81 g/mol
1304.52 g/mol
Halfwaardetijd
0.1 h
geen gegevens
Sequentie
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glugeen gegevens
Werkingsmechanisme
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
Bewijsbasis
Hoogste bewijs
Humane studie
Humane RCT
Studies
4
1
waarvan bij mensen
1
1
Geregistreerde effecten
3
1
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between DSIP and Icatibant?
- DSIP is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Icatibant?
- The highest available evidence level is "Humane studie" for DSIP and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Icatibant in Germany and the United States?
- Duitsland: DSIP — Niet goedgekeurd, Icatibant — Op recept. Verenigde Staten: DSIP — Niet goedgekeurd, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.